sc 7870  (Cell Signaling Technology Inc)

Journal: ACS Omega

Article Title: Synthesis and Antitumor Activity of Brominated-Ormeloxifene (Br-ORM) against Cervical Cancer

doi: 10.1021/acsomega.3c02277

Figure Lengend Snippet: Br-ORM decreases migration and invasion potential and attenuates EMT in cervical cancer cells. (A) Effect of Br-ORM on agarose bead assay. AB represents agarose bead, while MC represents migratory cells. (B) Representative images from a scratch wound healing assay demonstrating cervical cancer cell migration following the Br-ORM. (C) Effect of Br-ORM on the migratory potential of SiHa cells using the Boyden chamber assay. (D) Effect of Br-ORM treatment on invasion of SiHa cells as determined by a commercially available kit. (E) Western blot analysis of various EMT and associated effector protein following Br-ORM treatment in cervical cancer cells. (F) Effect of Br-ORM on mRNA levels of E-cadherin and N-cadherin as determined by qPCR (* p < 0.05). (G) Effect of Br-ORM on E-cadherin (green) in cervical cancer cells.

Article Snippet: We acquired β-actin (cat. no. 3700), Histone H3 (cat. no. 4499), N-cadherin (cat. no. 4061), Slug (cat. no. 9585), Snail (cat. no. 3879), Vimentin (cat. no. 5741), PARP (cat. no. 9532), MMP2 (cat. no. 4022), and MMP9 (cat. no. 13667) from Cell Signaling Technology Inc. β-catenin (cat. no. SC-7199) and E-cadherin (cat. no. SC-7870) antibodies were procured from Santa Cruz Biotechnology.

Techniques: Migration, Wound Healing Assay, Boyden Chamber Assay, Western Blot

Journal: ACS Omega

Article Title: Synthesis and Antitumor Activity of Brominated-Ormeloxifene (Br-ORM) against Cervical Cancer

doi: 10.1021/acsomega.3c02277

Figure Lengend Snippet: Br-ORM inhibits cervical tumor growth in an orthotopic xenograft mouse model. (A) Representative mouse images of control and Br-ORM-treated tumor-bearing mouse. (B) Line graph indicates regression of CaSki cell-derived xenograft tumor volume in Br-ORM-treated mice compared to the control group. (C) Bar graph representing tumor weight of control and Br-ORM-treated mice. (D) Effect of Br-ORM on the expression of E-cadherin, β-catenin, Vimentin, Snail, Slug, and PCNA as determined by immunohistochemistry in excised tumors of control and Br-ORM-treated mice.

Article Snippet: We acquired β-actin (cat. no. 3700), Histone H3 (cat. no. 4499), N-cadherin (cat. no. 4061), Slug (cat. no. 9585), Snail (cat. no. 3879), Vimentin (cat. no. 5741), PARP (cat. no. 9532), MMP2 (cat. no. 4022), and MMP9 (cat. no. 13667) from Cell Signaling Technology Inc. β-catenin (cat. no. SC-7199) and E-cadherin (cat. no. SC-7870) antibodies were procured from Santa Cruz Biotechnology.

Techniques: Derivative Assay, Expressing, Immunohistochemistry

Journal: Oncology Reports

Article Title: Development and characterization of a patient‑derived orthotopic xenograft of therapy‑resistant breast cancer

doi: 10.3892/or.2023.8536

Figure Lengend Snippet: Western blot analysis of breast cancer subtype-specific markers (A) PRa, PRb and epithelial and mesenchymal markers N-cadherin; (B) ERα, E-cadherin and Vimentin in tumor tissues from G1-G4 PDOXs. (C) Immunofluorescence analysis of the level of expression of ERα in PDOXs (G2 to G4) and DAPI for nuclear staining. PDOX, patient-derived orthotopic xenograft; ER, estrogen receptor; PR, progesterone receptor; G/Gen, generation.

Article Snippet: The cells were incubated overnight at 4°C with primary antibodies to the following proteins: estrogen receptor (ER)-α (cat. no. ab32063; Abcam), progesterone receptor (PR) (cat. no. ab8757; Cell Signaling Technology, Inc.), HER2 (cat. no. ab2428; Abcam), E-cadherin (cat. no. sc-7870; Santa Cruz Biotechnology, Inc.), N-cadherin (ab18203; Abcam), vimentin (sc-7558; Santa Cruz Biotechnology, Inc.), Ki-67 (sc-23900; Santa Cruz Biotechnology, Inc.), α-smooth muscle actin (SMA; ab5694; Abcam) and pan-cytokeratin (cat. no. C5992; Sigma-Aldrich; Merck Millipore) at 1:100 dilution.

Techniques: Western Blot, Immunofluorescence, Expressing, Staining, Derivative Assay

Journal: Oncology Reports

Article Title: Development and characterization of a patient‑derived orthotopic xenograft of therapy‑resistant breast cancer

doi: 10.3892/or.2023.8536

Figure Lengend Snippet: Immunofluorescence analysis of primary culture derived from PDOXs. (A and B) Established primary cultures were seeded on coverslips and fixed. (A) Primary cultures of G1 of PDOXs were stained with breast cancer subtype-specific markers, such as ERα, PRα and Ki-67 and epithelial and mesenchymal markers such as pan-CK, E-cadherin, vimentin and α-SMA. (B) Primary cultures of G4 of PDOXs were stained with breast cancer subtype-specific markers, ERα, PRα and Ki-67 and epithelial and mesenchymal markers such as Pan-CK N-Cadherin, Vimentin and α-SMA. PDOX, patient-derived orthotopic xenograft; SMA, smooth muscle actin; ER, estrogen receptor; PR, progesterone receptor; CK, cytokeratin.

Article Snippet: The cells were incubated overnight at 4°C with primary antibodies to the following proteins: estrogen receptor (ER)-α (cat. no. ab32063; Abcam), progesterone receptor (PR) (cat. no. ab8757; Cell Signaling Technology, Inc.), HER2 (cat. no. ab2428; Abcam), E-cadherin (cat. no. sc-7870; Santa Cruz Biotechnology, Inc.), N-cadherin (ab18203; Abcam), vimentin (sc-7558; Santa Cruz Biotechnology, Inc.), Ki-67 (sc-23900; Santa Cruz Biotechnology, Inc.), α-smooth muscle actin (SMA; ab5694; Abcam) and pan-cytokeratin (cat. no. C5992; Sigma-Aldrich; Merck Millipore) at 1:100 dilution.

Techniques: Immunofluorescence, Derivative Assay, Staining